Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of SNAIL through suppressing NOTCH/NF-κB and RAS/RAF/MEK/ERK signaling pathway

Publication date: Available online 8 June 2021Source: Acta Pharmaceutica Sinica BAuthor(s): Xiaoxia Yang, Pengfei Shang, Bingfang Yu, Qiuyang Jin, Jing Liao, Lei Wang, Jianbo Ji, Xiuli Guo
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research